Pemfigus Tedavisinde Rituksimab Kullanımı

Yıl 2017, Cilt: 2 Sayı: 2, 34 - 48, 25.10.2017

Bengü Gerçeker Türk , Ecem Bulut

Öz

Rituksimab  matür B hücrelerinin yüzeyinde bulunan CD20 antijenine bağlanan, sitolitik etkili, Ig G yapısında, kimerik, monoklonal bir antikordur. Rituksimab non-Hodgkin lenfoma, kronik lenfositik lösemi, romatoid artrit, mikroskobik polianjitis ve granülomatöz polianjitis (Wegener Granülomatozu’nda) tedavisinde endikedir.  Günümüzde çok sayıda otoimmün hastalık tedavisinde ve  2001 yılından beri de pemfigusta kullanılmaktadır.  Pemfigus tedavi rehberlerinde şimdilik üçüncü basamak tedavi ajanı olarak karşımıza çıkan rituksimab yakın gelecekte pemfigusun birinci basamak tedavisinde yerini alacak gibi gözükmektedir.  Bu derlemede güncel bilgiler ışığında pemfiguslu olgularda rituksimab kullanımı ile ilgili veriler ve kullanım ilkeleri ele alınmıştır. 

Kaynakça

• REFERANSLAR
• Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment--guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2015;29:405-14.
• Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13:833-44.
• Rituxan (rituximab) label. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf. Accessed March 27, 2015.
• Borradori L, Lombardi T, Samson J, Girardet C, Saurat JH, Hügli A. Anti-CD20monoclonal antibody (rituximab) for refractory erosive stomatitis secondary toCD20(+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137:269-72.
• Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al.; French study group on autoimmune bullous skin diseases. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017 20;389(10083):2031-40.
• Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up. Int Immunopharmacol. 2016;34:25-31.
• Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007;357:545-52.
• Schmidt E. Rituximab as first-line treatment of pemphigus. Lancet. 2017 20;389(10083):1956-1958.
• Pavanello F, Zucca E, Ghielmini M. Rituximab: 13 open questions after 20years of clinical use. Cancer Treat Rev. 2017;53:38-46.
• Lunardon L, Payne AS. Rituximab for autoimmune blistering diseases: recent studies, new insights. G Ital Dermatol Venereol. 2012 Jun;147(3):269-76.
• Kanwar AJ, Vinay K. Rituximab in pemphigus. Indian J Dermatol Venereol Leprol 2012;78(6):671-6.
• Müller R, Hunzelmann N, Baur V, Siebenhaar G, Wenzel E, Eming R, et al. Targeted immunotherapy with rituximab leads to a transient alterationof the IgG autoantibody profile in pemphigus vulgaris. Dermatol Res Pract.2010; 2010:321950.
• Feldman RJ, Christen WG, Ahmed AR. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol 2012; 166:511-7.
• El-Zawahry B, Bassiouny D, Hegazy R, et al. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs. Arch Dermatol Res. 2017 Jun 19.
• Colliou N, Picard D, Caillot F, et al. Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cel response. Sci Transl Med. 2013 6;5:175ra30.
• Buch MH, Smolen JS, Betteridge N, et al.; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximabin patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909-20.
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 ;68:1-26.
• Vinay K, Kanwar AJ, Mittal A, et al. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris. JAMA Dermatol. 2015;151:878-82..
• Uzun S. Pemfigusun güncel tedavisi ve yönetimi. Turk J Dermatol 2012; 6:91-101.
• Ingen-Housz-Oro S, Valeyrie-Allanore L, Cosnes A, et al. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids. JAMA Dermatol. 2015 ;151:200-3.
• Cianchini G, Lupi F, Masini C,et al. Therapy with rituximab for autoimmune pemphigus: Results from a single center observational study on 42 cases with long term follow-up. J Am Acad Dermatol 2012;67:617-22.
• Kasperkiewicz M, Eming R, Behzad M, et al. Efficacy and safety of rituximab in pemphigus:Experience of German Registry of Autoimmune Diseases. J Dtsch Dermatol Ges 2012;11.
• Uzun S, Bilgiç Temel A, Akman Karakaş A, et al. Efficacy and safety of rituximab therapy in patients with pemphigus vulgaris: first report from Turkey. Int J Dermatol. 2016 ;55:1362-1368.
• Cho HH, Jin SP, Chung JH. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities. J Eur Acad Dermatol Venereol. 2013 Jan 29.
• Leshem YA, Hodak E, David M, Anhalt GJ, Mimouni D. Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: a retrospective study of 47 patients. J Am Acad Dermatol. 2013;68:404-11.
• Kanwar AJ, Vinay K, Sawatkar GU, Dogra S, Minz RW, Shear NH, Koga H, Ishii N, Hashimoto T. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study. Br J Dermatol. 2014 ;170:1341-9.
• Craythorne E, du Viver A, Mufti GJ, Warnakulasuriya S. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations. J Oral Pathol Med. 2011 ;40:616-20.
• Kim JH, Kim YH, Kim MR, Kim SC. Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients. Br J Dermatol. 2011;165:646 51.
• Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2012;166:405-12.
• Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65:552-8.
• Zakka LR, Shetty SS, Ahmed AR. Rituximab in the treatment of pemphigus vulgaris. Dermatol Ther (Heidelb). 2012;2:17.
• Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006 Oct 26;355:1772-9.
• Ahmed AR, Kaveri S, Spigelman Z. Long-Term Remissions in Recalcitrant Pemphigus Vulgaris. N Engl J Med. 2015 31;373:2693-4.
• Ahmed AR, Shetty S, Kaveri S, Spigelman ZS. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-yearfollow-up. J Am Acad Dermatol. 2016;74:700-8.
• Kim TH, Choi Y, Lee SE, Lim JM, Kim SC. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up. J Dermatol. 2017; 44:615-620.
• Ahmed AR, Shetty S. A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev. 2015; 14 : 323-31.
• Greenblatt DT, Benton EC, Groves RW, Setterfield JF. Crescendo response to rituximab in oral pemphigus vulgaris: a case with 7-year follow-up. Clin Exp Dermatol. 2016;41:529-32.
• Gregoriou S, Giatrakou S, Theodoropoulos K, Katoulis A, Loumou P, Toumbis-Ioannou E, Papadavid E, Avgerinou G, Stavrianeas N, Rigopoulos D. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial. Dermatology. 2014;228:158-65.
• Heelan K, Al-Mohammedi F, Smith MJ, Knowles S, Lansang P, Walsh S, Shear NH. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol. 2014;150:703-8.
• Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patientswith rheumatoid arthritis treated with rituximab in the autoimmunity and rituximabregistry. Arthritis Rheum 2010 ; 62 : 2625-32 .
• Polansky M, Patel N, Feldman R. Complete remission after rituximab therapy in an HIV-positive patient with pemphigus vulgaris. Br J Dermatol. 2015;173:1557-9.
• Kanwar AJ, Vinay K, Heelan K, Walsh S, Shear NH, Dhiman RK. Use of rituximab in pemphigus patients with chronic viral hepatitis: report of three cases. Indian J Dermatol Venereol Leprol. 2014;80:422-6.
• Vinay K, Kanwar AJ, Sawatkar GU, Dogra S, Ishii N, Hashimoto T. Successful use of rituximab in the treatment of childhood and juvenile pemphigus. J Am Acad Dermatol. 2014;71:669-75.
• Bittenbring JT et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphomatreated with but not without rituximab. J Clin Oncol 2014;32:3242–8.
• Levin AS, Otani IM, Lax T, Hochberg E, Banerji A. Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review. J Allergy Clin Immunol Pract. 2017;5:107-113.
• Fatourechi MM, el-Azhary RA, Gibson LE. Rituximab : applications in dermatology. Int J Dermatol. 2006;45:1143-1155.
• Vogel WH. Infusion reactions: diagnosis, assessment and management. Clin J Oncol Nurs. 2010;14: E10-21.
• Chi Chiu Mok. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014; 8: 87–100.
• Assouline S et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol 2016;3:e128–38.
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005; 31:456-473.
• Wei KC, Wang YH, Wang WH, Chen W. Fatal infection of Pneumocystis jirovecipneumonia in a pemphigus patient treated with rituximab. J Eur Acad Dermatol Venereol. 2017;31:e350-e351.
• Wei KC, Wang YH, Wang WH, Chen W. Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab. J Eur Acad Dermatol Venereol. 2017 Jan 27.
• Shetty S, Ahmed AR. Preliminary analysis of mortality associated withrituximab use in autoimmune diseases. Autoimmunity. 2013;46:487-96.
• Cattaneo C et al. Delayed-onset peripheral blood cytopenia after rituximab:frequency and risk factor assessment in a consecutive series of 77 treatments.Leuk Lymphoma 2006;47:1013-7.
• Feldman RJ. Paradoxical worsening of pemphigus vulgaris following rituximab therapy. Br J Dermatol. 2015;173:858-9.
• Heelan K, Hassan S, Bannon G, Knowles S, Walsh S, Shear NH, Mittmann N. Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab. J Cutan Med Surg. 2015;19:274-82.